Administrative Supplement to Real-time Wideband Cardiac MRI for Patients with a Cardiac Implantable Electronic Device

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $680,708
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    Pending
  • Research Location

    United States of America
  • Lead Research Institution

    NORTHWESTERN UNIVERSITY AT CHICAGO
  • Research Priority Alignment

    N/A
  • Research Category

    Epidemiological studies

  • Research Subcategory

    Disease susceptibility

  • Special Interest Tags

    N/A

  • Study Subject

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Project Summary/Abstract: While primary manifestations of severe acute respiratory syndrome coronavirus(SARS-CoV-2) infection involve the respiratory system, acute myocardial injury occurs as frequently up to27%, and the 30-day mortality rate is substantially higher in patients with myocardial injury (51.2%) than thosewithout injury (4.5%). Another disturbing trend is the disproportionate impact of COVID-19 on the blackpopulation across the US. In Chicago, blacks (30.1% of population) account for 50.5% of COVID-19 patientsand 69.6% of COVID-19 deaths. These statistics highlight the need to establish the overall prevalence,mechanism, severity, and extent of cardiac injury associated with SARS-CoV-2 and investigate factorscontributing to such glaring health disparities associated with COVID-19. Our primary hypothesis is that acute myocardial injury is more prevalent, extensive, and severe inhospitalized patients with COVID-19 compared to matched hospitalized patients with ORV. Furthermore, wehypothesize that acute myocardial injury associated with SARS-CoV-2 is worse in blacks than whites. To testthese hypotheses, we propose to conduct a case-control study comparing hospitalized patients with COVID-19to hospitalized patients with ORV matched for sex, age, race, viral pneumonia risk score (MuLBSTA), and pre-existing heart disease (coronary artery disease or heart failure). We will enroll equal numbers of whites andblacks to determine factors contributing to racial health disparities in patients with COVID-19. Cardiovascular magnetic resonance (CMR) is the ideal "one-stop-shop" imaging test for phenotypingpatients with virus-mediated cardiac injury associated with multiple pathways and manifestations. Thisapproach affords comprehensive assessment of injury, including evaluation of inflammation, necrosis or scar,diffuse fibrosis, contractile function, and hemodynamics. The image quality of a standard CMR, however, maybe unacceptable in hospitalized COVID-19 patients due to two fundamental methodologic deficiencies: (a)lengthy (~60 min) scan time which is too long for sick patients; (b) severe image artifacts caused by dyspnea(55%), arrhythmia (16.7%) and alveolar infiltrates (off-resonance). Leveraging our access to a library of rapid,wideband, arrhythmia-insensitive, free-breathing CMR pulse sequences that were developed for the parentstudy (R01HL151079), we are in a unique position to perform a rapid (20 min) free-breathing CMR tophenotype this cohort who otherwise may not be considered for CMR. The specific objectives of this study are:(a) to determine whether acute myocardial injury differs significantly between COVID-19 and ORV patients; (b)to determine whether cardiac injury differs across race and correlates with social determinants of health; (c) todetermine whether the severity of cardiac injury correlates with the degree of lung injury as assessed withchest X-ray and MuLBSTA. This proposal has high potential impact because new discoveries of cardiac injuryand racial disparities will serve as the requisite evidence for pursuing future therapeutic studies.